Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

328.50

Mkt cap

7.7B

Volume

382K

High

348.35

P/E Ratio

-15.90

52-wk high

377.46

Low

326.70

Div yield

N/A

52-wk low

189.00

Madrigal Pharmaceuticals reported a Q1 2024 GAAP EPS loss of $(7.38), missing the consensus estimate of $(6.17) by 19.61%.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:21 am

Today's session highlighted significant whale activity in the health care sector, focusing on options trading for stocks like BMY, ARDX, AMGN, BDX, HROW, CI, MDGL, DXCM, LLY, and TMDX. The trades varied in sentiment, with some being bullish and others bearish, across a range of expiration dates and strike prices. This activity could indicate upcoming volatility or trading opportunities in these stocks.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 5:35 pm

B of A Securities has initiated coverage on Madrigal Pharmaceuticals (MDGL) with an Underperform rating and set a price target of $150.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 10:19 am

Evercore ISI Group analyst Liisa Bayko has maintained an Outperform rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $325 to $405.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 3:26 pm

Madrigal Pharmaceuticals announced the pricing of its upsized $600 million public offering of 750,000 shares at $260 per share, causing its stock to trade lower.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 11:12 am

Madrigal Pharmaceuticals, Inc. (MDGL) has announced the pricing of an upsized public offering of 750,000 shares at $260 per share, along with pre-funded warrants for 1,557,692 shares at $259.9999 each. This move is aimed at raising funds to support its efforts in developing treatments for nonalcoholic steatohepatitis (NASH).

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 6:13 am

Madrigal Pharmaceuticals has announced a proposed public offering of $500 million worth of common stock and pre-funded warrants. This move is aimed at raising capital, potentially for further research, development, and expansion of its operations.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:05 pm

Today's session highlighted significant whale activity in the health care sector, focusing on options trading for 10 companies. The trades varied in sentiment, with both bullish and bearish positions taken across a range of expiration dates and strike prices. Notable activity included bullish calls on HROW, ZTS (despite being a put), SHC, ABBV, and AMGN, and bearish positions on IMTX, LQDA, MDGL, DXCM, and LLY (despite being a put). This activity could indicate investor expectations and market movements.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 5:35 pm

Jabil Inc. shares fell over 14% after reporting Q2 results and FY25 guidance below estimates. Other stocks also showed significant movement, with notable gainers including Verb Technology and Better Therapeutics, and losers like C3is Inc. and SELLAS Life Sciences.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 6:31 pm

UBS analyst Eliana Merle maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $337 to $410.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 5:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.